COMPARING COST-UTILITY OF DMARDs IN AUTOANTIBODY-NEGATIVE RHEUMATOID ARTHRITIS PATIENTS.

Like Comment
To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative rheumatoid arthritis(RA-) patients, according to 2010 criteria.For this analysis we selected all RA- patients within the intermediate probability stratum of the tREACH trial. The tREACH had a treat-to-target approach, aiming for low disease activity(DAS<2.4) and treatment adjustments could occur every 3 months. Initial treatment strategies consisted of methotrexate 25mg/week(iMTX), hydroxychloroquine 400mg/day(iHCQ) or an oral glucocorticoids tapering scheme without DMARDs(iGCs). Data on Quality adjusted life-years(QALYs), measured with the EQ-5D-3L, healthcare and productivity costs were used.Average QALYs(sd), for iMTX, iHCQ and iGCs were respectively 0.71(0.14), 0.73(0.14) and 0.71(0.15). The average total costs(sd) for iMTX, iHCQ and iGCs were respectively €10.832(14.763), €11.208 (12.801) and €10.502(11.973). Healthcare costs were mainly determined by biological costs, which were significantly lower in the iHCQ group compared to iGCs(p


View the full article @ Rheumatology (Oxford, England)


Get PDF with LibKey
Authors: Luurssen-Masurel Nathalie, Mulligen van Elise, Weel Angelique Elisabeth Adriana Maria, Hazes Johanna Maria Wilhelmina, Jong Pascal Hendrik Pieter de, tREACH group investigators

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
5710 Contributions
2 Followers
0 Following